Company news

Todos Medical Ltd. (OTC:TOMDF) news

Todos Medical Ltd. news releases on 6ix. Latest, Jun 23, 2022: Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study…

Todos Medical Ltd. (OTC:TOMDF) news

Press releases — page 2

Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID

Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff

Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics

Todos Medical Reports Day 45 Update for Case Study #6

Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction

CEO Presenting on the Emerging Growth Conference on June 8 Register Now

Todos Medical to Present at The LD Micro Conference

Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET

Todos Medical Reports Day 26 Update For Case Study #4

Todos Medical Releases Corporate Update

Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference

Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022

CEOs Presenting at the Emerging Growth Conference on April 27; Register Now

Todos Medical to Present at the Emerging Growth Conference

Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics

Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

Update: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates

Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates

Todos Medical Reports Case Study of Patient with Long COVID

Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products

Todos Medical to Present at the Proactive One2One Virtual Forum

Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma

UPDATE -- CEO Presenting on the Emerging Growth Conference on March 16 Register Now

Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

TODOS Medical Special Virtual Conference Register Now

Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®

Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022

Todos Medical CEO Provides Letter to Shareholders

CEO Presenting on the Emerging Growth Conference on January 5 Register Now

Todos Medical to Present at January 5, 2022 Emerging Growth Conference

Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista

Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing

Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States

Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing

Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics

Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19

Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes

Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST

Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics

CEOs Presenting at the Emerging Growth Conference on December 8; Register Now